Example of Journal of Cardiovascular Pharmacology and Therapeutics format
Recent searches

Example of Journal of Cardiovascular Pharmacology and Therapeutics format Example of Journal of Cardiovascular Pharmacology and Therapeutics format Example of Journal of Cardiovascular Pharmacology and Therapeutics format Example of Journal of Cardiovascular Pharmacology and Therapeutics format Example of Journal of Cardiovascular Pharmacology and Therapeutics format Example of Journal of Cardiovascular Pharmacology and Therapeutics format Example of Journal of Cardiovascular Pharmacology and Therapeutics format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of Journal of Cardiovascular Pharmacology and Therapeutics format Example of Journal of Cardiovascular Pharmacology and Therapeutics format Example of Journal of Cardiovascular Pharmacology and Therapeutics format Example of Journal of Cardiovascular Pharmacology and Therapeutics format Example of Journal of Cardiovascular Pharmacology and Therapeutics format Example of Journal of Cardiovascular Pharmacology and Therapeutics format Example of Journal of Cardiovascular Pharmacology and Therapeutics format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access

Journal of Cardiovascular Pharmacology and Therapeutics — Template for authors

Publisher: SAGE
Categories Rank Trend in last 3 yrs
Cardiology and Cardiovascular Medicine #87 of 317 down down by 27 ranks
Pharmacology (medical) #86 of 246 down down by 49 ranks
Pharmacology #130 of 297 down down by 54 ranks
journal-quality-icon Journal quality:
Good
calendar-icon Last 4 years overview: 242 Published Papers | 1033 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 02/06/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access

Springer

Quality:  
High
CiteRatio: 6.5
SJR: 1.108
SNIP: 1.077
open access Open Access

Wiley

Quality:  
Good
CiteRatio: 4.2
SJR: 0.818
SNIP: 0.742
open access Open Access

SAGE

Quality:  
High
CiteRatio: 6.1
SJR: 1.333
SNIP: 1.061
open access Open Access

SAGE

Quality:  
High
CiteRatio: 4.8
SJR: 1.164
SNIP: 1.22

Journal Performance & Insights

Impact Factor

CiteRatio

Determines the importance of a journal by taking a measure of frequency with which the average article in a journal has been cited in a particular year.

A measure of average citations received per peer-reviewed paper published in the journal.

2.322

10% from 2018

Impact factor for Journal of Cardiovascular Pharmacology and Therapeutics from 2016 - 2019
Year Value
2019 2.322
2018 2.57
2017 2.936
2016 3.0
graph view Graph view
table view Table view

4.3

2% from 2019

CiteRatio for Journal of Cardiovascular Pharmacology and Therapeutics from 2016 - 2020
Year Value
2020 4.3
2019 4.4
2018 4.8
2017 5.8
2016 5.5
graph view Graph view
table view Table view

insights Insights

  • Impact factor of this journal has decreased by 10% in last year.
  • This journal’s impact factor is in the top 10 percentile category.

insights Insights

  • CiteRatio of this journal has decreased by 2% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

0.787

17% from 2019

SJR for Journal of Cardiovascular Pharmacology and Therapeutics from 2016 - 2020
Year Value
2020 0.787
2019 0.674
2018 0.877
2017 1.272
2016 1.127
graph view Graph view
table view Table view

0.865

33% from 2019

SNIP for Journal of Cardiovascular Pharmacology and Therapeutics from 2016 - 2020
Year Value
2020 0.865
2019 0.649
2018 0.701
2017 0.83
2016 0.857
graph view Graph view
table view Table view

insights Insights

  • SJR of this journal has increased by 17% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has increased by 33% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

Journal of Cardiovascular Pharmacology and Therapeutics

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

SAGE

Journal of Cardiovascular Pharmacology and Therapeutics

The Journal of Cardiovascular Pharmacology and Therapeutics publishes original basic human studies, original animal studies, and original bench research with potential clinical application to cardiovascular pharmacology and therapeutics. The focus of the experimental studies i...... Read More

Medicine

i
Last updated on
02 Jun 2020
i
ISSN
1074-2484
i
Impact Factor
High - 1.005
i
Open Access
Yes
i
Sherpa RoMEO Archiving Policy
Green faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
SageV
i
Citation Type
Numbered (Superscripted)
25
i
Bibliography Example
Blonder GE, Tinkham M and Klapwijk TM. Transition from metallic to tunneling regimes in superconducting microconstrictions: Excess current, charge imbalance, and supercurrent conversion. Phys. Rev. B 1982; 25(7): 4515–4532. URL 10.1103/PhysRevB.25.4515.

Top papers written in this journal

Journal Article DOI: 10.1177/1074248413511693
Characterization of the Adenosine Pharmacology of Ticagrelor Reveals Therapeutically Relevant Inhibition of Equilibrative Nucleoside Transporter 1
Duncan Armstrong1, Claire Summers2, Lorna Ewart2, Sven Nylander2, James E. Sidaway2, J.J.J. van Giezen2

Abstract:

Introduction:Studies have shown that ticagrelor has a further adenosine-mediated mechanism of action in addition to its potent inhibition of the P2Y12 receptor, which may explain some of ticagrelor’s clinical characteristics. This study aimed to further characterize the adenosine pharmacology of ticagrelor, its major metaboli... Introduction:Studies have shown that ticagrelor has a further adenosine-mediated mechanism of action in addition to its potent inhibition of the P2Y12 receptor, which may explain some of ticagrelor’s clinical characteristics. This study aimed to further characterize the adenosine pharmacology of ticagrelor, its major metabolites, and other P2Y12 receptor antagonists.Methods:Inhibition of nucleoside transporter-mediated [3H]adenosine uptake by ticagrelor, its major metabolites, and alternative P2Y12 antagonists was examined in recombinant Madin-Darby canine kidney (MDCK) cells. The pharmacology of ticagrelor and its major metabolites at adenosine A1, A2A, A2B, and A3 receptor subtypes was examined using in vitro radioligand binding and functional assays and ex vivo C-fiber experiments in rat and guinea pig vagus nerves.Results:Ticagrelor (and less effectively its metabolites) and the main cangrelor metabolite inhibited [3H]adenosine uptake in equilibrative nucleoside transporter (ENT) 1-expressing MDCK cel... read more read less

Topics:

Equilibrative nucleoside transporter (61%)61% related to the paper, Equilibrative nucleoside transporter 1 (59%)59% related to the paper, P2Y12 (56%)56% related to the paper, Adenosine (56%)56% related to the paper, Ticagrelor (54%)54% related to the paper
212 Citations
Journal Article DOI: 10.1177/1074248410395941
Direct thrombin inhibitors.
P. Joshua O’Brien1, Leila Mureebe1

Abstract:

Cardiovascular disease is a leading cause of death and pathologic coagulation plays an integral role in the development, propagation, and intervention of cardiovascular disease. The 2 classic anticoagulants, heparin and vitamin K antagonists, though having served humanity for nearly a century, are both inconvenient and nonspe... Cardiovascular disease is a leading cause of death and pathologic coagulation plays an integral role in the development, propagation, and intervention of cardiovascular disease. The 2 classic anticoagulants, heparin and vitamin K antagonists, though having served humanity for nearly a century, are both inconvenient and nonspecific. Through both direct and indirect roles, thrombin is essential to coagulation, and makes for a very attractive target in medical intervention of pathologic thrombosis. This article will review the nature of direct thrombin inhibitors, current indications, and ongoing trials. read more read less

Topics:

Discovery and development of direct thrombin inhibitors (60%)60% related to the paper, Thrombin (52%)52% related to the paper
209 Citations
Journal Article DOI: 10.1177/107424840100600102
Arterial elastance and wave reflection augmentation of systolic blood pressure: deleterious effects and implications for therapy.
Wilmer W. Nichols1, David G. Edwards1

Abstract:

Systolic and pulse blood pressures are stronger predictors of stroke, coronary heart disease, myocardial infarction, heart failure, end-stage renal disease, and cardiovascular mortality than diastolic pressure. Furthermore, diastolic pressure is inversely related to coronary heart disease and cardiovascular mortality. Increas... Systolic and pulse blood pressures are stronger predictors of stroke, coronary heart disease, myocardial infarction, heart failure, end-stage renal disease, and cardiovascular mortality than diastolic pressure. Furthermore, diastolic pressure is inversely related to coronary heart disease and cardiovascular mortality. Increased elastance (or stiffness, inverse of compliance) of the central elastic arteries is the primary cause of increased systolic and pulse pressure with advancing age and in patients with cardiovascular disease, including hypertension, and is due to degeneration and hyperplasia of the arterial wall; diastolic pressure decreases as arterial elastance increases. As elastance increases, transmission velocity of both forward and backward (or reflected) traveling waves increases, which causes the reflected wave to arrive earlier in the central aorta and augments pressure in late systole. These changes in arterial wall properties cause an increase in left ventricular afterload and myocardial oxygen consumption and a decrease in myocardial perfusion pressure, which may induce an imbalance in the supply-demand ratio, especially in hypertrophied hearts with coronary artery disease. Also, an increase in systolic pressure increases arterial wall circumferential stress, which promotes fatigue and development of atherosclerosis. Vasodilator drugs have little direct active effect on large elastic arteries but can markedly reduce wave reflection amplitude and augmentation index by decreasing elastance of the muscular arteries and reducing pulse wave velocity of the reflected wave from the periphery to the heart. This decrease in intensity (or amplitude) and increase in travel time (or delay) of the reflected wave causes a generalized decrease in systolic pressure and arterial wall stress and an increase in ascending aortic flow during the deceleration phase. The decrease in systolic pressure brought about by this mechanism is grossly underestimated when systolic pressure is measured in the brachial artery. read more read less

Topics:

Pulse pressure (69%)69% related to the paper, Blood pressure (65%)65% related to the paper, Pulse wave velocity (61%)61% related to the paper, Vascular resistance (55%)55% related to the paper, Heart failure (55%)55% related to the paper
178 Citations
Journal Article DOI: 10.1177/1074248411410883
Ticagrelor Inhibits Adenosine Uptake In Vitro and Enhances Adenosine-Mediated Hyperemia Responses in a Canine Model:
J.J.J. van Giezen1, James E. Sidaway1, Philip Glaves1, Ian Kirk1, Jan-Arne Björkman1

Abstract:

Aims: A routine secondary pharmacology screen indicated that reversibly binding oral P2Y12 receptor antagonist ticagrelor could inhibit adenosine uptake in human erythrocytes, suggesting that ticagrelor may potentiate adenosine-mediated responses in vivo. The aim of this study was to further characterize the adenosine uptake ... Aims: A routine secondary pharmacology screen indicated that reversibly binding oral P2Y12 receptor antagonist ticagrelor could inhibit adenosine uptake in human erythrocytes, suggesting that ticagrelor may potentiate adenosine-mediated responses in vivo. The aim of this study was to further characterize the adenosine uptake inhibition in vitro and study possible physiological consequences of adenosine uptake inhibition by ticagrelor in an anesthetized dog model of coronary blood flow compared to dipyridamole. Methods and Results: We measured [2-3H]adenosine uptake in purified human erythrocytes and several cell lines in the presence of ticagrelor or the known uptake inhibitor dipyridamole as a comparator. Using an open-chest dog model (beagles), we measured the left anterior descending (LAD) coronary artery blood flow during reactive hyperemia after 1 minute occlusion or intracoronary infusion of adenosine before and after administration of vehicle, ticagrelor, or dipyridamole (each n = 8). Ticagrelor co... read more read less

Topics:

Adenosine (60%)60% related to the paper, Ticagrelor (58%)58% related to the paper, Reactive hyperemia (57%)57% related to the paper, Dipyridamole (52%)52% related to the paper
178 Citations
Journal Article DOI: 10.1177/1074248416686187
Metabolic Syndrome: Clinical and Policy Implications of the New Silent Killer
Dawn Harris Sherling1, Parvathi Perumareddi1, Charles H. Hennekens1

Abstract:

The United States is experiencing its greatest life expectancy ever. Nonetheless, the general health of the US population is far from at an all-time high. An important contributor to the pandemic o... The United States is experiencing its greatest life expectancy ever. Nonetheless, the general health of the US population is far from at an all-time high. An important contributor to the pandemic o... read more read less

Topics:

Life expectancy (57%)57% related to the paper, Population (57%)57% related to the paper
174 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for Journal of Cardiovascular Pharmacology and Therapeutics.

It automatically formats your research paper to SAGE formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

Journal of Cardiovascular Pharmacology and Therapeutics format uses SageV citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write Journal of Cardiovascular Pharmacology and Therapeutics in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the Journal of Cardiovascular Pharmacology and Therapeutics guidelines and auto format it.

2. Do you follow the Journal of Cardiovascular Pharmacology and Therapeutics guidelines?

Yes, the template is compliant with the Journal of Cardiovascular Pharmacology and Therapeutics guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in Journal of Cardiovascular Pharmacology and Therapeutics?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the Journal of Cardiovascular Pharmacology and Therapeutics citation style.

4. Can I use the Journal of Cardiovascular Pharmacology and Therapeutics templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for Journal of Cardiovascular Pharmacology and Therapeutics.

5. Can I use a manuscript in Journal of Cardiovascular Pharmacology and Therapeutics that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper Journal of Cardiovascular Pharmacology and Therapeutics that you can download at the end.

6. How long does it usually take you to format my papers in Journal of Cardiovascular Pharmacology and Therapeutics?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in Journal of Cardiovascular Pharmacology and Therapeutics.

7. Where can I find the template for the Journal of Cardiovascular Pharmacology and Therapeutics?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Journal of Cardiovascular Pharmacology and Therapeutics's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the Journal of Cardiovascular Pharmacology and Therapeutics's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. Journal of Cardiovascular Pharmacology and Therapeutics an online tool or is there a desktop version?

SciSpace's Journal of Cardiovascular Pharmacology and Therapeutics is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like Journal of Cardiovascular Pharmacology and Therapeutics?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like Journal of Cardiovascular Pharmacology and Therapeutics?”

11. What is the output that I would get after using Journal of Cardiovascular Pharmacology and Therapeutics?

After writing your paper autoformatting in Journal of Cardiovascular Pharmacology and Therapeutics, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is Journal of Cardiovascular Pharmacology and Therapeutics's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for Journal of Cardiovascular Pharmacology and Therapeutics?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for Journal of Cardiovascular Pharmacology and Therapeutics. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In Journal of Cardiovascular Pharmacology and Therapeutics?

The 5 most common citation types in order of usage for Journal of Cardiovascular Pharmacology and Therapeutics are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the Journal of Cardiovascular Pharmacology and Therapeutics?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Journal of Cardiovascular Pharmacology and Therapeutics's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download Journal of Cardiovascular Pharmacology and Therapeutics in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in Journal of Cardiovascular Pharmacology and Therapeutics Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Journal of Cardiovascular Pharmacology and Therapeutics formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template